Anixa Biosciences Inc (ANIX) Stock Price, Quote & News

Company Profile

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs comprising the development of liraltagene autoleucel, a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer. The company also engaged in the development of a vaccine against breast cancer; and the development of a vaccine discovery pro...

Industry: Biotechnology

Sector: Healthcare

Phone: 408 708 9808

Website: www.anixa.com

Address:

3150 Almaden Expressway, Suite 250, San Jose, United States

Searchingforthecure Mar. 16 at 4:31 PM

$ANIX amit should enroll Susie wiles and help accelerate the vaccine through FDA process. https://www.cnn.com/2026/03/16/politics/trumps-chief-of-staff-has-been-diagnosed-with-early-stage-breast-cancer-president-says?cid=android_app

0 · Reply

StockNews_Live Mar. 12 at 2:40 PM

$ANIX 🎯 STOCK NEWS ALERT 💵 Price: $2.88 (-2.04%) 🔥 Sentiment Score: 85/100 🚀 VERY POSITIVE NEWS 📄 Anixa Biosciences, Inc. announced that its Chairman and CEO, Dr. Amit Kumar, is featured on the Water Tower Research Healthcare Happenings podcast. During the podcast, Dr. Kumar discussed the… 📎 https://stocknews.live/news/ANIX/anixa-biosciences-featured-on-25091.html

0 · Reply

focafoca99 Mar. 11 at 10:41 PM

$ANIX filing was about shareholder matters and the annual-meeting presentation

0 · Reply

PenkeInvesting Mar. 10 at 11:33 PM

Fundamental analysis of $ANIX (Anixa Biosciences Inc) based on financial data and reported results. #ANIX

0 · Reply

jjnewly27 Mar. 10 at 12:48 PM

$ANIX nice move before opening

0 · Reply

jjnewly27 Mar. 9 at 10:11 PM

$ZVRA take a look at $ANIX and $ESPR all looking good

0 · Reply

jjnewly27 Mar. 9 at 10:09 PM

$ANIX earnings beat

0 · Reply

Kher33 Mar. 9 at 8:32 PM

$ANIX https://ir.anixa.com/sec-filings/content/0001493152-26-009370/form10-q.htm

0 · Reply

Pedelco Mar. 9 at 7:04 PM

$ANIX fuck cancer

0 · Reply

TravisBking87 Mar. 9 at 4:49 PM

$SLS $IBRX $VSTM $ANIX I can not agree more! the filthy shorts are the worst!

1 · Reply

Anixa Biosciences Featured on Water Tower Research Healthcare Happenings Podcast

Mar 9, 2026, 8:30 AM EDT - 8 days ago

Anixa Biosciences Receives Notice of Allowance from Korean Ministry of Intellectual Property (MOIP) for Patent Covering Breast Cancer Vaccine Technology

Mar 2, 2026, 9:10 AM EST - 15 days ago

Anixa Biosciences to Host 2026 Annual Meeting of Stockholders and Provide Corporate Update Highlighting Recent Clinical and Regulatory Progress

Feb 23, 2026, 8:55 AM EST - 22 days ago

Anixa Biosciences Announces Dr. Jose Conejo-Garcia will Keynote the South Carolina Clinical & Translational Research Institute 2026 Retreat

Feb 9, 2026, 8:00 AM EST - 5 weeks ago

Anixa Biosciences Reports Encouraging Patient Survival Observations in Ovarian Cancer CAR-T Trial; Achieves Regulatory Approval Enabling Major Dose Escalation

Feb 9, 2026, 7:31 AM EST - 5 weeks ago

EXCLUSIVE: Anixa Biosciences' Ovarian Cancer Drug Candidate Shows Longer Survival With No Major Safety Issues

Feb 2, 2026, 9:00 AM EST - 6 weeks ago

Anixa Biosciences Secures United States Adopted Names Council Approval of Non-Proprietary Name for its CAR-T Therapy, a Key Step Toward Future Commercialization

Jan 27, 2026, 8:30 AM EST - 7 weeks ago

Anixa Biosciences Receives Notice of Allowance from Mexican Institute of Industrial Property (IMPI) for Patent Covering Breast Cancer Vaccine Technology

Jan 21, 2026, 3:54 PM EST - 7 weeks ago

Water Tower Research Publishes Initiation of Coverage Report on Anixa Biosciences, Inc., “Anixa's T-Cell Innovations Show Breakthrough Potential in Solid Tumors”

Dec 15, 2025, 8:45 AM EST - 3 months ago

Anixa Biosciences Announces Transfer of IND for Breast Cancer Vaccine from Cleveland Clinic

Dec 11, 2025, 6:02 PM EST - 3 months ago

Anixa Biosciences Announces Positive Phase 1 Data for Investigational Breast Cancer Vaccine; Primary Endpoints Were Met and Immune Response Observed in 74% of Participants

Dec 10, 2025, 9:00 AM EST - 3 months ago

Anixa Biosciences to Participate in Water Tower Research Fireside Chat on Monday, December 15, 2025

Nov 17, 2025, 6:17 PM EST - 4 months ago

Anixa Biosciences, Inc. (ANIX) Discusses Differentiated CAR-T Therapy and Breast Cancer Vaccine Clinical Programs Transcript

Nov 17, 2025, 8:15 AM EST - 4 months ago

Anixa Biosciences Announces World Health Organization (WHO) Approval of International Non-Proprietary Name for its CAR-T Therapy, Marking a Key Milestone Toward Global Recognition and Future Commercialization

Nov 12, 2025, 11:00 AM EST - 4 months ago

Water Tower Research Issues Statement Regarding Technical Interruption During Anixa Biosciences Fireside Chat

Nov 12, 2025, 9:00 AM EST - 4 months ago

Anixa Biosciences Awarded Key U.S. Patent Expanding Breast Cancer Vaccine IP Protection into 2040s

Nov 10, 2025, 10:30 AM EST - 4 months ago

Anixa Biosciences to Participate in Water Tower Research Fireside Chat on Tuesday, November 11, 2025

Nov 5, 2025, 8:55 AM EST - 4 months ago

Anixa Biosciences Announces Execution of Data Transfer Agreement with Cleveland Clinic

Oct 23, 2025, 8:45 AM EDT - 5 months ago

Anixa Biosciences to Present at the Spartan Capital Securities Second Annual Investor Conference

Oct 20, 2025, 8:25 AM EDT - 5 months ago

Anixa Biosciences Announces Issuance of Chinese Patent Covering Breast Cancer Vaccine Technology

Oct 7, 2025, 8:30 AM EDT - 5 months ago

Anixa Biosciences Announces Completion of Final Patient Visit in Breast Cancer Vaccine Clinical Trial

Sep 22, 2025, 8:05 AM EDT - 6 months ago

Cleveland Clinic to Present Final Results of Phase 1 Clinical Trial for Anixa Biosciences' Breast Cancer Vaccine at 2025 San Antonio Breast Cancer Symposium

Sep 8, 2025, 8:00 AM EDT - 6 months ago

Anixa Biosciences and Moffitt Cancer Center Complete Dosing of Fourth Cohort in Ovarian Cancer CAR-T Clinical Trial; Multiple Patients Surpassing Median Expected Survival

Sep 2, 2025, 8:54 AM EDT - 7 months ago

Anixa Biosciences Announces Time Change for Presentation at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 25, 2025, 9:13 AM EDT - 7 months ago

Anixa Biosciences to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 20, 2025, 8:37 AM EDT - 7 months ago

Anixa Biosciences Receives Notice of Allowance from Chinese National Intellectual Property Administration for Patent Covering Breast Cancer Vaccine Technology

Aug 18, 2025, 9:00 AM EDT - 7 months ago

Anixa Biosciences Announces Treatment of Second Patient in Fourth Cohort of Ovarian Cancer CAR-T Clinical Trial

Aug 12, 2025, 8:05 AM EDT - 7 months ago

Anixa Biosciences Announces Issuance of Additional U.S. Patent for CAR-T Technology

Aug 8, 2025, 9:15 AM EDT - 7 months ago

Anixa Biosciences Announces Dr. Robert Wenham will speak about Immunotherapy in surviving Ovarian Cancer at the 13th Annual Ovarcoming Cancer Conference

Aug 4, 2025, 8:45 AM EDT - 8 months ago

Anixa Biosciences Announces Commencement of US FDA Approved IND Transfer to Support Upcoming Phase 2 Breast Cancer Vaccine Trial

Jul 30, 2025, 8:15 AM EDT - 8 months ago

Anixa Biosciences Receives Notice of Allowance from Canadian Intellectual Property Office for Patent Covering Breast Cancer Vaccine Technology

Jul 24, 2025, 8:00 AM EDT - 8 months ago

Anixa Biosciences Awarded New U.S. Patent Extending Breast Cancer Vaccine IP Protection into 2040s

Jul 15, 2025, 3:49 PM EDT - 8 months ago

Anixa Biosciences: Oncology Platform With Asymmetric Upside

Jul 9, 2025, 8:00 AM EDT - 8 months ago

Anixa Biosciences Announces Issuance of Additional U.S. Patent for Ovarian Cancer Vaccine Technology

Jun 23, 2025, 8:00 AM EDT - 9 months ago

Anixa Biosciences Initiates Dosing in Fourth Cohort in its Ovarian Cancer CAR-T Clinical Trial

Jun 20, 2025, 7:30 AM EDT - 9 months ago

Anixa Biosciences to Host an Investor Webcast on June 26, 2025

Jun 10, 2025, 7:00 AM EDT - 10 months ago

Anixa Biosciences' Breast Cancer Vaccine Receives National News Coverage

Jun 9, 2025, 8:00 AM EDT - 10 months ago

Anixa Biosciences Announces Poster Presentation on Ovarian Cancer CAR-T Clinical Trial at the ESMO Gynaecological Cancers Congress 2025

Jun 3, 2025, 7:25 AM EDT - 10 months ago

Anixa Biosciences' Breast Cancer Vaccine Featured in NewsNation Interview

Jun 2, 2025, 7:00 AM EDT - 10 months ago

Anixa Biosciences Announces Completion of Enrollment in Phase 1 Trial of Breast Cancer Vaccine

May 19, 2025, 8:00 AM EDT - 10 months ago

Anixa Biosciences CEO Provides Letter to Shareholders Outlining Significant Progress and Advancement Towards Potentially Transformative Milestones

May 12, 2025, 8:00 AM EDT - 11 months ago

Anixa Biosciences Announces Poster Presentation on Ovarian Cancer CAR-T Clinical Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 30, 2025, 8:00 AM EDT - 11 months ago

Anixa Biosciences to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 20th

Apr 14, 2025, 8:00 AM EDT - 1 year ago

Anixa Biosciences Receives Notice of Allowance from U.S. Patent and Trademark Office for CAR-T Technology, Further Strengthening its Robust Intellectual Property Portfolio

Apr 9, 2025, 8:00 AM EDT - 1 year ago

Anixa Biosciences Receives Notice of Allowance from U.S. Patent and Trademark Office for Patent Covering Breast Cancer Vaccine Technology

Apr 1, 2025, 8:00 AM EDT - 1 year ago

Anixa Biosciences to Present at the Jones Las Vegas Healthcare and Technology Innovation Conference on April 9th

Mar 25, 2025, 8:00 AM EDT - 1 year ago

Anixa Biosciences Enters Letter of Intent with VERDI Solutions to Develop Artificial Intelligence-Guided Personalized and Off-the-Shelf Cancer Vaccines

Mar 24, 2025, 8:00 AM EDT - 1 year ago

Anixa Biosciences Receives Notice of Allowance from USPTO for Ovarian Cancer Vaccine

Mar 17, 2025, 8:00 AM EDT - 1 year ago

Anixa Biosciences CEO to Present at the 2025 CAGLA NeauxCancer Conference on March 28th

Mar 10, 2025, 8:30 AM EDT - 1 year ago

Anixa Biosciences 2025 Annual Meeting of Stockholders to Include Investor Presentation Open to All Interested Parties

Searchingforthecure Mar. 16 at 4:31 PM

0 · Reply

StockNews_Live Mar. 12 at 2:40 PM

0 · Reply

focafoca99 Mar. 11 at 10:41 PM

$ANIX filing was about shareholder matters and the annual-meeting presentation

0 · Reply

PenkeInvesting Mar. 10 at 11:33 PM

Fundamental analysis of $ANIX (Anixa Biosciences Inc) based on financial data and reported results. #ANIX

0 · Reply

jjnewly27 Mar. 10 at 12:48 PM

$ANIX nice move before opening

0 · Reply

jjnewly27 Mar. 9 at 10:11 PM

$ZVRA take a look at $ANIX and $ESPR all looking good

0 · Reply

jjnewly27 Mar. 9 at 10:09 PM

$ANIX earnings beat

0 · Reply

Kher33 Mar. 9 at 8:32 PM

$ANIX https://ir.anixa.com/sec-filings/content/0001493152-26-009370/form10-q.htm

0 · Reply

Pedelco Mar. 9 at 7:04 PM

$ANIX fuck cancer

0 · Reply

TravisBking87 Mar. 9 at 4:49 PM

$SLS $IBRX $VSTM $ANIX I can not agree more! the filthy shorts are the worst!

1 · Reply

Wontscalp4blow Mar. 9 at 3:09 PM

$SLS $IBRX $VSTM $ANIX ill say it for you!!! When they get approval, I hope we get reports on every news channel, about people jumping out of buildings, for trying to short a life savung treatment into the ground.

1 · Reply

Brypannebecker Mar. 9 at 3:08 PM

$ANIX $IBRX $SLS $VSTM

0 · Reply

jacksparo Mar. 9 at 3:07 PM

$SLS $IBRX $VSTM $ANIX If I were to say everything and if I were to say the full truth about how bad some shorts are, I might no longer be available, so I will say I am praying every day to win over the cancer because it will save millions of lives around the world! I am sure shorts hate me for a reason! But on the other hand, I got a lot of support from great retailers and honest traders! https://www.foxnews.com/politics/cure-cancer-would-deliver-100-trillion-economic-windfall-report-says

1 · Reply

DARKP00L Mar. 9 at 1:04 PM

$ANIX 08:38 on Mar. 09 2026 Anixa Biosciences Receives South Korean Patent Allowance For Breast Cancer Vaccine Technology Licensed From Cleveland Clinic #tradeideas

0 · Reply

TheTradeXchange Mar. 9 at 12:32 PM

$ANIX - Anixa Biosciences Receives Notice of Allowance from Korean Ministry of Intellectual Property (MOIP) for Patent Covering Breast Cancer Vaccine Technology

0 · Reply

Stocktradexxx Mar. 4 at 9:52 PM

Great coverage on NBC Chicago $ANIX https://www.nbcchicago.com/video/local/vaccine-aimed-at-preventing-and-treating-aggressive-breast-cancer-being-tested/3903136/

2 · Reply

Pedelco Mar. 4 at 12:52 PM

$ANIX fuck cancer, I believe

0 · Reply

TheRealShortSqueezy Mar. 3 at 8:00 PM

$ATAI : Can Recent Milestones and Upcoming Catalysts Drive Momentum? 📈 Recent milestones and pipeline progress from AtaiBeckley continue to support long-term shareholder value, the chart may be starting to reflect that shift. 🚨Technical view: ➡️ Major support: $3.40–$3.70 ➡️ Extended multi-month decline ➡️ Tight consolidation near lows ➡️ Volume expansion needed on any breakout 📊 📈Reclaim levels to watch: ➡️ $4.20–$4.40 near-term resistance ➡️ $4.75–$5.20 pivot zone ➡️ $5.55–$5.90 prior breakdown area ➡️ $6.25–$6.75 major resistance ➡️ $7.00+ momentum breakout A strong move back above $4.40–$4.75 with volume would be the first sign of momentum shifting. For now, it’s a support hold until proven otherwise. 📈 Communicated disclaimer: https://bit.ly/4ci8Ftu Sector Peers: $HELP $RLMD $SLS $ANIX

0 · Reply

TheRealShortSqueezy Mar. 3 at 2:57 PM

TheRealShortSqueezy @TheShortSqueezy · 6s $ATAI: Recent News Strengthens Analyst Conviction ATAIBeckley is seeing increasing analyst conviction following the release of key clinical milestones and recent business developments. Latest Analyst Update: HC Wainwright & Co. has maintained its Buy rating on ATAI while raising its price target to $25.00 from $15.00, a 66.67% increase. Recent Analyst Coverage: Guggenheim – $11 price target (Jan 20, 2026) JonesTrading – $16 price target Canaccord Genuity – PT raised to $14 from $11 (+27%) Needham – $12 price target Institutional Activity: ARK Invest increased its position in Q4 2025 by 1,286,446 shares (+63.7%) ARK now holds 3,305,997 shares. Rising price targets, institutional buying, and continued execution reflect growing confidence in ATAIBeckley’s strategy and long-term potential. 📊 Communicated disclaimer: https://bit.ly/4ci8Ftu Sector Peers: $RLMD $SLS $ANIX $RGLS

0 · Reply

Kher33 Mar. 2 at 3:55 PM

$ANIX https://ir.anixa.com/press-releases/detail/1113

0 · Reply

TheRealShortSqueezy Feb. 26 at 2:01 PM

$ATAI Delivers Major Development News🔬🧬 ATAI Life Sciences continues advancing its clinical pipeline following multiple recent milestones. Recent Key Milestones 🎯 The company has reported several important advancements across its pipeline and leadership: ➡️Positive Phase 2a topline results for EMP-01 in social anxiety disorder, providing early clinical proof-of-concept ➡️Continued development of core pipeline assets, including: 🥇BPL-003: progressing toward late-stage development 🥈VLS-01: currently in Phase 2 clinical trials ➡️Strengthened executive leadership with the appointment of a new Chief Financial Officer These developments highlight accelerating pipeline momentum heading into 2026 Investor Conferences 👇 🗓️March 4th: TD Cowen 46th Annual Health Care Conference 🗓️March 10th: Jefferies 2026 Biotech on the Beach 🗓️March 11th: Leerink Global Healthcare Conference Communicated Disclaimer : https://bit.ly/3OCJhol Sector Peers: $SLS $ANIX $RGLS $VNDA

1 · Reply

BillionerOfKing Feb. 26 at 4:02 AM

$ANIX Current Stock Price: $3.01 Contracts to trade: $2.5 ANIX Mar 20 2026 Call Entry: $1.35 Exit: $2.47 ROI: 83% Hold ~30 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

Market Cap	94.88M
Revenue (ttm)	0.00
Net Income (ttm)	-10.93M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	32,869
Avg Vol	171,980
Day's Range	N/A - N/A
Shares Out	33.53M
Stochastic %K	28%
Beta	0.48
Analysts	Strong Sell
Price Target	$10.00